摘要：Intensive chemotherapy regimens with or without stem cell transplantation are the current standard treatment in patients with acute myeloid leukemia (AML). The identifi- cation of new mutations in AML may provide the basis for a more targeted therapeutic approach. In one or several genetic subsets, some new drugs, as single drug or in com- bination with s tandard antileukemic drugs, demonstrated promising results. Typical ex- amples are tyros ine kinase inhibitors, such as dasatinib for f c-Kit mutated core binding factor positive AML or FLT-3 inhibitors, such as midostaur in or sorafenib, in cases with FLT-3 mutations. Clofarabine is a second generation hybrid pur ine nucleoside ana- logue: standard induction regimens containing clofarabine provided a high remission rates in patients with intermediate and high r is k AML. In patients unf it for intensive che- motherapy, treatment with hypomethilating agents is widely used. Gemtuzumab ozo- gamicin, anti-CD33 monoclonal antibody conjugated to calicheamicin, has shown signif icant antileukemic activity in older patients with relapsed AML
